Proteomics analysis from aggressive human cancers can help identify potential therapeutic targets
Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets.
They report in the journal
Oncogene, the identification of proteomic signatures that are associated with clinical measures of aggressive disease for each of the seven cancer types studied. Some signatures were shared between different types of cancer and included cellular pathways of altered metabolism. Importantly, experimental results provided proof-of-concept that their proteomics analysis approach is a valuable strategy to identify potential therapeutic targets.
Compound isolated from Moroccan fungus shows promise to fight triple negative breast cancer
A compound isolated from a fungus growing on the roots of a flowering plant in Morocco shows promise as a powerful opponent of aggressive triple negative breast cancer, scientists say.
They have early evidence that the peptide EnnA, isolated from a fungus living symbiotically with a flowering plant known for its penchant of trapping flies, directly inhibits the natural and powerful cell protector HSP90, which cancer hijacks to help avoid attack by the immune system.
EnnA lets the immune system do what it should by getting HSP90 out of the way. We are very excited about how this compound is affecting tumors.
sign up for our newsletter become a community member Community Members have access to our e-edition and can sign up for our daily e-newsletter
Already a Member?Sign in Sign up now
Palinuro Italian Cuisine celebrates first anniversary
Palinuro Italian Cuisine serves soups, pastas, salads, specialized meat dishes and other Italian meals. (Courtesy Palinuro Italian Cuisine)
Palinuro Italian Cuisine serves soups, pastas, salads, specialized meat dishes and other Italian meals. (Courtesy Palinuro Italian Cuisine)
Now is the chance to help your local community succeed. Become a Patron by contributing to
Community Impact Newspaper and gain daily insight into what s happening in your own backyard. Thank you for reading and supporting community journalism.
A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.
Using two different viruses to tackle tumors
An international research group led by the University of Basel has developed a promising strategy for therapeutic cancer vaccines. Using two different viruses as vehicles, they administered specific tumor components in experiments on mice with cancer in order to stimulate their immune system to attack the tumor. The approach is now being tested in clinical studies.
Making use of the immune system as an ally in the fight against cancer forms the basis of a wide range of modern cancer therapies. One of these is therapeutic cancer vaccination: following diagnosis, specialists set about determining which components of the tumor could function as an identifying feature for the immune system. The patient is then administered exactly these components by means of vaccination, with a view to triggering the strongest possible immune response against the tumor.